Aquestive Therapeutics (AQST) Stock: Buy, Sell, or Hold?
AQST - Aquestive Therapeutics, Inc. Common Stock
$4.00
-0.13 (-3.15%)
▼
5d:
+5.82%
30d:
-17.01%
90d:
+7.24%
BUY
HIGH Confidence
Analysis Updated: Oct 23, 2026 12:00 AM ET
Earnings: Nov 04, 2026
9d
Get Alerted When AQST Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: AQST shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
✅ BUY SIGNAL: AQST shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
In-depth Analysis How we analyze
Valuation Analysis: AQST is currently trading at $4.00, which is considered oversold relative to its 30-day fair value range of $4.21 to $4.86.
Technical Outlook: Technically, AQST is in a strong uptrend. Immediate support is located at $3.65, while resistance sits at $4.89. Short-term momentum is weak, with the stock down 3.1% recently.
Market Sentiment: AQST scores 73/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $9.33 (+133.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, AQST is in a strong uptrend. Immediate support is located at $3.65, while resistance sits at $4.89. Short-term momentum is weak, with the stock down 3.1% recently.
Market Sentiment: AQST scores 73/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $9.33 (+133.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$4.21 -
$4.86
Company Quality Score
65/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
89.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (73/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.1%)
- BULLISH: Trading 133.3% below Wall St target ($9.33)
- BULLISH: Bottoming setup score 73/100 — corrected, stabilizing, and turning up
Trading Range Analysis
30-Day Trading Range
$4.21 -
$4.86
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$3.65
Resistance Level
$4.89
Current Trend
Strong Uptrend
Technical data as of
Oct 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-7.02
Wall Street Target
$9.33
(+133.3%)
Revenue Growth (YoY)
38.1%
Profit Margin
-144.6%
Share & Embed Analysis
Last updated: October 24, 2026 7:03 PM ET
Data refreshes hourly during market hours. Next update: 8:03 PM
Data refreshes hourly during market hours. Next update: 8:03 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is AQST showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
29 analysts |
$207 | 56 HOLD |
|
ELAN
Elanco Animal Health |
STRONG BUY
16 analysts |
$31 | 47 HOLD |
|
ALKS
Alkermes Plc |
STRONG BUY
19 analysts |
$56 | 38 SELL |
|
AMLX
Amylyx Pharmaceuticals I… |
STRONG BUY
12 analysts |
$43 | 54 HOLD |
|
HROW
Harrow Health Inc |
STRONG BUY
9 analysts |
$65 | 60 HOLD |
